Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 BI-836826
1.2.3 ALT-803
1.2.4 BMS-986016
1.2.5 CC-122
1.2.6 Others
1.3 Market by Application
1.3.1 Global Indolent Lymphoma Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Indolent Lymphoma Treatment Market Perspective (2019-2030)
2.2 Indolent Lymphoma Treatment Growth Trends by Region
2.2.1 Global Indolent Lymphoma Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Indolent Lymphoma Treatment Historic Market Size by Region (2019-2024)
2.2.3 Indolent Lymphoma Treatment Forecasted Market Size by Region (2025-2030)
2.3 Indolent Lymphoma Treatment Market Dynamics
2.3.1 Indolent Lymphoma Treatment Industry Trends
2.3.2 Indolent Lymphoma Treatment Market Drivers
2.3.3 Indolent Lymphoma Treatment Market Challenges
2.3.4 Indolent Lymphoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Indolent Lymphoma Treatment Players by Revenue
3.1.1 Global Top Indolent Lymphoma Treatment Players by Revenue (2019-2024)
3.1.2 Global Indolent Lymphoma Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Indolent Lymphoma Treatment Revenue
3.4 Global Indolent Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Indolent Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Indolent Lymphoma Treatment Revenue in 2023
3.5 Indolent Lymphoma Treatment Key Players Head office and Area Served
3.6 Key Players Indolent Lymphoma Treatment Product Solution and Service
3.7 Date of Enter into Indolent Lymphoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Indolent Lymphoma Treatment Breakdown Data by Type
4.1 Global Indolent Lymphoma Treatment Historic Market Size by Type (2019-2024)
4.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2025-2030)
5 Indolent Lymphoma Treatment Breakdown Data by Application
5.1 Global Indolent Lymphoma Treatment Historic Market Size by Application (2019-2024)
5.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Indolent Lymphoma Treatment Market Size (2019-2030)
6.2 North America Indolent Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Indolent Lymphoma Treatment Market Size by Country (2019-2024)
6.4 North America Indolent Lymphoma Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Indolent Lymphoma Treatment Market Size (2019-2030)
7.2 Europe Indolent Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Indolent Lymphoma Treatment Market Size by Country (2019-2024)
7.4 Europe Indolent Lymphoma Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Indolent Lymphoma Treatment Market Size (2019-2030)
8.2 Asia-Pacific Indolent Lymphoma Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Indolent Lymphoma Treatment Market Size (2019-2030)
9.2 Latin America Indolent Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Indolent Lymphoma Treatment Market Size by Country (2019-2024)
9.4 Latin America Indolent Lymphoma Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Indolent Lymphoma Treatment Market Size (2019-2030)
10.2 Middle East & Africa Indolent Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altor BioScience Corporation
11.1.1 Altor BioScience Corporation Company Detail
11.1.2 Altor BioScience Corporation Business Overview
11.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Introduction
11.1.4 Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.1.5 Altor BioScience Corporation Recent Development
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Detail
11.2.2 Amgen Inc. Business Overview
11.2.3 Amgen Inc. Indolent Lymphoma Treatment Introduction
11.2.4 Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.2.5 Amgen Inc. Recent Development
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Detail
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.3.5 Astellas Pharma Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Detail
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Indolent Lymphoma Treatment Introduction
11.4.4 Bayer AG Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.4.5 Bayer AG Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Detail
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Detail
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Detail
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Indolent Lymphoma Treatment Introduction
11.7.4 Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.7.5 Celgene Corporation Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Introduction
11.8.4 Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.8.5 Eli Lilly and Company Recent Development
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 F. Hoffmann-La Roche Ltd. Company Detail
11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
11.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Introduction
11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
11.10 Gilead Sciences, Inc.
11.10.1 Gilead Sciences, Inc. Company Detail
11.10.2 Gilead Sciences, Inc. Business Overview
11.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Introduction
11.10.4 Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.10.5 Gilead Sciences, Inc. Recent Development
11.11 Incyte Corporation
11.11.1 Incyte Corporation Company Detail
11.11.2 Incyte Corporation Business Overview
11.11.3 Incyte Corporation Indolent Lymphoma Treatment Introduction
11.11.4 Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.11.5 Incyte Corporation Recent Development
11.12 Infinity Pharmaceuticals, Inc.
11.12.1 Infinity Pharmaceuticals, Inc. Company Detail
11.12.2 Infinity Pharmaceuticals, Inc. Business Overview
11.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Introduction
11.12.4 Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.12.5 Infinity Pharmaceuticals, Inc. Recent Development
11.13 Juno Therapeutics Inc.
11.13.1 Juno Therapeutics Inc. Company Detail
11.13.2 Juno Therapeutics Inc. Business Overview
11.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Introduction
11.13.4 Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.13.5 Juno Therapeutics Inc. Recent Development
11.14 MedImmune, LLC
11.14.1 MedImmune, LLC Company Detail
11.14.2 MedImmune, LLC Business Overview
11.14.3 MedImmune, LLC Indolent Lymphoma Treatment Introduction
11.14.4 MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2019-2024)
11.14.5 MedImmune, LLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details